Epiregulin (EREG), human recombinant

Epiregulin (EREG), human recombinant is available at Gentaur for Next week delivery.

A ligand of EGFR, and most members of the ERBB family

Biomolecule/Target: Epiregulin

Alternates names: Epiregulin, EREG

Synonyms: Epiregulin, EREG

Background Information: Epiregulin is part of the EGF family. Epiregulin functions as a ligand of EGFR, as well as a ligand of most members of the ERBB (v-erb-b2 oncogene homolog) family of tyrosine-kinase receptors. Epiregulin is expressed mostly in the placenta and peripheral blood leukocytes and in specific carcinomas of the bladder, lung, kidney and colon. Epiregulin stimulates the proliferation of keratinocytes, hepatocytes, fibroblasts and Vascular smooth muscle cells. Epiregulin inhibits the growth of several tumor-derived epithelial cell lines. Human Epiregulin is initially synthesized as a glycosylated 19.0 kDa transmembrane precursor protein, which is processed by proteolytic cleavage to produce a 6.0 kDa mature secreted sequence. Recombinant human EREG produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 50 amino acids and having a molecular mass of 6 kDa.

Reconstitution Instructions: Reconstitute in sterile H₂O to 0.1–1 mg /ml. The solution can then further diluted to other aqueous solutions.

NCBI Gene Symbol: EREG

Gene ID: 2069

NCBI Accession: O14944